The broad and ‘extremely competent’ offering at Osborne Clarke often assists clients which are active within the medtech and pharma industries, particularly in relation to rare diseases. Thomas Devred leads the team, and is well equipped to advise on licensing, market access, and supply chain issues, in addition to handling data privacy issues involving patient data. Regulatory expert Léa Masson-Boukobza often acts for medical device and pharma clients in matters involving anti-gift rules, advertising, and clinical trials.
Testimonials
Collated independently by Legal 500 research team.
‘The team is extremely competent and fully invested in answering the questions asked. I warmly recommend this team and in particular Thomas Devred who is a very great professional.’
‘Thomas Devred has extensive experience in this field. His industry experience is a major asset in answering the questions and expectations of his clients.’
‘In-depth analysis, quality of exchanges, responsiveness and availability.’
‘Léa Masson-Boukobza - in-depth analyses and quality advice, responsiveness. Thomas Devred - responsiveness, taking into account constraints and internal policies in the analysis of the cases presented to him.’
‘Diverse expertise.’
‘Very responsive and available, always ready to support the customer.’
Key clients
- Act for Health - Pro Case Management
- Amryt Pharmaceuticals
- Corin
- FédéPSAD
- Grifols
- Horizon Therapeutics
- Karl Storz
- Santhera Pharmaceuticals
- Revolution Medicines
- Unicancer
- pharma&
Work highlights
- Advised Grifols on the acquisition of Biotest and integration of compassionate use programmes for pharma products.
- Advised Karl Storz on an R&D cooperation to train artificial intelligence with patients' data and upgrade medical devices.
- Advised Santhera Pharma on digital communication for the launch of a rare disease pharma product.
Practice head
The lawyer(s) leading their teams.
Thomas Devred